What's new

Human medicines European public assessment report (EPAR): Penbraya, Meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed), Date of authorisation: 14/11/2024, Status: Withdrawn

Human medicines European public assessment report (EPAR): Penbraya, Meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed), Date of authorisation: 14/11/2024, Status: Withdrawn

Feb 9, 2025 - 21:46
 0
Human medicines European public assessment report (EPAR): Penbraya, Meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed), Date of authorisation: 14/11/2024, Status: Withdrawn
Human medicines European public assessment report (EPAR): Penbraya, Meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed), Date of authorisation: 14/11/2024, Status: Withdrawn
Read More

Tags:

Previous Article

Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) me...

Next Article

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Pro...

Related Posts

Human medicines European public assessment report (EPAR): Victoza, liraglutide, Date of authorisation: 30/06/2009, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 20, 2025  0

Summary of opinion: Prevymis, 27/02/2025 Positive

Summary of opinion: Prevymis, 27/02/2025 Positive

Feb 28, 2025  0

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025  0